US Stock MarketDetailed Quotes
MLTX MoonLake Immunotherapeutics
- 54.240
- +1.400+2.65%
Close Nov 27 16:00 ET
- 54.240
- 0.0000.00%
Post 16:01 ET
3.42BMarket Cap-42708P/E (TTM)
54.600High52.370Low78.86KVolume53.090Open52.840Pre Close4.22MTurnover0.31%Turnover RatioLossP/E (Static)63.06MShares64.98052wk High7.01P/B1.40BFloat Cap37.55052wk Low--Dividend TTM25.81MShs Float64.980Historical High--Div YieldTTM4.22%Amplitude4.250Historical Low53.528Avg Price1Lot Size
About MoonLake Immunotherapeutics Company
Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.
Company Profile
SymbolMLTX
Company NameMoonLake Immunotherapeutics
Listing DateOct 20, 2020
Founded2021
CEODr. Jorge Santos da Silva
MarketNASDAQ
Employees50
Fiscal Year Ends12-31
AddressDorfstrasse 29
CityZug
ProvinceZug
CountrySwitzerland
Zip Code6300
Phone41-510-80-22
Websitehttp://www.moonlaketx.com
Company Executives
- Name
- Position
- Salary
- Dr. Jorge Santos da Silva
- Chief Executive Officer and Director
- 1.20M
- Dr. Kristian Reich
- Chief Scientific Officer
- 1.23M
- Matthias Bodenstedt
- Chief Financial Officer and Principal Accounting Officer
- 891.60K
- Simon John Sturge
- Chairman of the Board
- 315.49K
- Dr. Kara Lassen
- Independent Director
- 44.00K
- Spike Loy
- Independent Director
- 277.49K
- Dr. Ramnik Xavier
- Independent Director
- 299.99K
- Dr. Andrew Phillips, PhD
- Independent Director
- 280.99K
- Catherine Moukheibir
- Independent Director
- 287.49K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data